Mode
Text Size
Log in / Sign up
N/A Completed N=62 Randomized Single-blind Treatment

Restylane Defyne in a Stepwise Treatment Approach

Lower Face Folds and Lines
Source: ClinicalTrials.gov NCT04520997 ↗
Enrolled (actual)
62
Serious AEs
0.0%
Results posted
Apr 2023
Primary outcomePrimary: Number of Participants (Responders) With Aesthetic Improvement by the Treating Investigator Assessment Using Global Aesthetic Improvement Scale (GAIS) at Week 3 — 18; 12; 10; 8 Participants

Summary

This was a 12-week study to evaluate the effectiveness and safety of Restylane Defyne when using two different injection approaches, stepwise down-up vs. top-down, when treating the lower face.

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants (Responders) With Aesthetic Improvement by the Treating Investigator Assessment Using Global Aesthetic Improvement Scale (GAIS) at Week 3
18; 12; 10; 8; 3; 9
PRIMARY
Percentage of Participants (Responders) With Aesthetic Improvement Based on Treating Investigator Assessment Using GAIS at Week 6
56.7; 75.9; 36.7; 17.2; 6.7; 6.9
PRIMARY
Percentage of Participants (Responders) With Aesthetic Improvement Based on Treating Investigator Assessment Using GAIS at Week 9
76.7; 71.4; 20.0; 17.9; 3.3; 10.7
SECONDARY
Percentage of Participants With Naturalness of the Treatment Result as Assessed by Treating Investigator
90.3; 89.7; 9.7; 10.3; 90.0; 89.7
SECONDARY
Percentage of Participants Agreeing With Statements in a Satisfaction Questionnaire (SSQ)
100; 93.1; 93.3; 93.1; 96.7; 89.3

Eligibility Criteria

Inclusion Criteria

  • Subjects willed to comply with the requirements of the study and provided a signed written informed consent
  • Subjects willed to undergo augmentation and correction therapy in the studied indications
  • Adult males or non-pregnant, non-breastfeeding females and women of non-child bearing potential over the age of 21

Exclusion Criteria

  • Known/previous allergy or hypersensitivity to any injectable hyaluronic acid (HA) gel or to gram-positive bacterial proteins
  • Previous use of any permanent (non-biodegradable) treatment, lifting threads, permanent implants or autologous fat below the level of the horizontal line from the lower orbital rim
  • Participation in any interventional clinical study within 30 days of screening
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04520997). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search